It has been indicated that high IDO1 expression is linked with a poor outcome in GBM patients, and an IDO1 blockade with an IDO1 inhibitor Epacadostat (INCB024360) or Indoximod achieves good therapeutic efficacy in glioma-bearing mice [9,10]. The gene discussed is IDO1; the disease is central nervous system cancer.